Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (17952)	3/26/1998 9:40:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

I suspect that the FDA figured that they want the most current data and since the trial was completed, they wanted LGND to do the analysis and include the final (instead of interim) data in the filing. Since the Bear Stearns' report already hinted at at 2Q filing, I suspect that the delay isn't that new to institutions, which may be why they are on the sidelines. It is LGND's first NDA and it's always hard to nail down exactly what the FDA wants, but it certainly looks like LGND will deliver the goods and they may be able to trade off a more robust filing for a quicker review.

To: RXGOLF who wrote (17952)	3/26/1998 9:44:00 PM
From: Machaon	Read Replies (4) \| Respond to of 32384

Interesting points from the Panretin gel article: <==================================================================== " ... we have decided to take an additional six to eight weeks to file our NDA on Panretin gel for KS. ... may also simplify or shorten the review time by the agency, helping to minimize time to market," ====================================================================> So..... on the one hand, a delay. On the other hand, perhaps a faster approval?! I wonder if the Market will consider this more on the positive side? Is the glass half full, or half empty? <=================================================================== Results of the Phase III North American trial ... demonstrated that 35.1 percent (47 of 134) ... experienced complete or partial response. Patients in the Panretin gel group had the option of continuing treatment ... The response rate (complete and partial response) was 49 percent (66 of 134) ====================================================================> Damn, that stuff is good! It blows my mind to think that skin cancer can be treated with a gel! I wonder how Panretin stacks up against the other forms of skin cancer? Well...... not meaning to hype this stock, but....... GO LGND!!! Regards, and good luck, Bob